Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized maintenance study of MASCT-I after first-line chemotherapy benefit in advanced urothelial carcinoma
CTR20221634Phase 2Active
- Sponsor
- Hengrui Yuanzheng
- Start
- Jan 2023
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of MASCT-1 in transitional cell carcinoma (TCC), sponsored by Hengrui Yuanzheng. Started Jan 2023; status: active.
02
Drugs
MASCT-1
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20221634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221634.